Neuroendocrine Tumors
361
71
103
145
Key Insights
Highlights
Success Rate
81% trial completion
Published Results
59 trials with published results (16%)
Research Maturity
145 completed trials (40% of total)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 49/100
9.4%
34 terminated out of 361 trials
81.0%
-5.6% vs benchmark
8%
28 trials in Phase 3/4
41%
59 of 145 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 145 completed trials
Clinical Trials (361)
Lu-177-DOTATATE (Lutathera) in Combination With Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine Tumors (GEP-NET)
Study of Cabozantinib in Participants With Neuroendocrine Tumors Who Have Already Received Prior Treatment
Lu-DOTATATE Treatment in Patients With 68Ga-DOTATATE Somatostatin Receptor Positive Neuroendocrine Tumors
Comparing DLL3 PET/CT to Standard Scans in Neuroendocrine Cancer
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
Tissue Procurement and Natural History Study of Neuroendocrine Neoplasms (NENs) Including Adrenocortical Carcinoma (ACC)
Study of RYZ401 in Subjects With Solid Tumors Expressing SSTRs.
EQUITY GI: A Prospective Study to Enhance Quality, Inclusivity, and Trial Participation in Black Patients With Gastrointestinal Cancer.
Clinico-biological Database in Patients Treated With Metabolic Radiotherapy in the Nuclear Medicine Department
SwissNET - a Registry for Neuroendocrine Tumours in Switzerland
Cessation of Somatostatin Analogues After PRRT in Mid, Hind-Gut and Pancreatic Neuroendocrine Tumours
Iconographic Registry of Pancreatobiliary Endoscopy Procedures
A Study to Evaluate a New Way to Identify/Diagnose Tumours With Somatostatin Receptors Using [68]Ga-HA-DOTATATE and to Ensure it is Safe to Use
Multicenter Retrospective Database on Prognostic and Predictive Factors in Patients With Neuroendocrine Tumors
Follow Up Protocol for Subjects Previously Enrolled on NCI Surgery Branch Studies
Safety/Efficacy Study of CID-078 in Patients With Advanced Solid Tumor Malignancies
Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma
Trial of Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) of the Gastrointestinal Tract, Lung, or Pancreas Who Have Not Received Prior Treatment With mTOR Inhibitors
Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
Neuroendocrine Tumors - Patient Reported Outcomes